COVID-19 and liver injury: where do we stand?
1st Department of Internal Medicine, 417 Army Share Fund Hospital of Athens (Nikolaos Papadopoulos).
2nd Department of Internal Medicine, Hippokration General Hospital of Athens, Medical School of National & Kapodistrian University of Athens (Sofia Vasileiadi, Melanie Deutsch), Greece.
- Published Article
Annals of gastroenterology
- Publication Date
Jan 01, 2020
The coronavirus SARS-CoV-2 was identified as the cause of COVID-19, a severe acute respiratory syndrome. Several clinical studies refer to liver injury as the most frequent clinical extrapulmonary manifestation. In this review, we summarize the available clinical data concerning liver injury during COVID-19. Although the underlying mechanism of liver impairment is somewhat unclear, transaminases and bilirubin levels are elevated in a substantial proportion of patients. Moreover, more severe alterations in liver enzymes may correlate with a worse clinical course of COVID-19. However, several other cofactors, such as drug-induced liver injury, hyper-inflammatory response to infection, hypoxic hepatitis or preexisting underlying liver disease, cannot be excluded. Copyright: © Hellenic Society of Gastroenterology.
Report this publication
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 10/06/2020 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/32879591